Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial -

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Respiratory disorders
Summary
RCT (n=449) reported that ramucirumab plus erlotinib demonstrated superior progression-free survival versus placebo plus erlotinib at a median of 20.7 months follow up (19.4 vs 12.4 months; HR 0.59; 95% CI 0.46–0.76; p<0.0001).
UKMi comment
A related commentary compares and contrasts the findings of RELAY with NEJ026, which demonstrated improved progression free survival with erlotinib and bevacizumab in a similar population.
Related links: Comment